A Phase I Study of the WT1 peptide vaccine for the post-transplant AML at 2nd remissio
Phase 1
- Conditions
- Acute myeloid leukemia 2nd remission(post allogeneic stem cell transplantation)
- Registration Number
- JPRN-UMIN000013289
- Lead Sponsor
- Osaka University Graduate school of medicine, Pediatrics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with Down syndrome 2.Patients who relapsed less than 6 months after the end of initial therapy 3.Patients who suffered from uncontrollable infection and organ failure 4.Patients who suffered from active GVHD
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method